Equities analysts expect that Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) will post earnings per share (EPS) of ($0.17) for the current quarter, according to Zacks. Zero analysts have made estimates for Cyclacel Pharmaceuticals’ earnings, with estimates ranging from ($0.17) to ($0.16). Cyclacel Pharmaceuticals posted earnings per share of ($0.18) in the same quarter last year, which would suggest a positive year-over-year growth rate of 5.6%. The firm is scheduled to issue its next earnings results on Monday, November 11th.
On average, analysts expect that Cyclacel Pharmaceuticals will report full-year earnings of ($0.62) per share for the current financial year, with EPS estimates ranging from ($0.68) to ($0.54). For the next year, analysts expect that the business will post earnings of ($0.58) per share, with EPS estimates ranging from ($0.65) to ($0.50). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Cyclacel Pharmaceuticals.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01).
Separately, Zacks Investment Research cut shares of Cyclacel Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 16th.
Shares of Cyclacel Pharmaceuticals stock opened at $0.37 on Wednesday. The company has a current ratio of 7.26, a quick ratio of 7.26 and a debt-to-equity ratio of 0.08. The company has a 50-day simple moving average of $0.40 and a 200 day simple moving average of $0.57. Cyclacel Pharmaceuticals has a 12-month low of $0.28 and a 12-month high of $1.49.
A hedge fund recently raised its stake in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC raised its stake in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 82.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,102,400 shares of the biotechnology company’s stock after acquiring an additional 498,200 shares during the quarter. Renaissance Technologies LLC owned about 6.41% of Cyclacel Pharmaceuticals worth $596,000 as of its most recent filing with the Securities and Exchange Commission. 8.96% of the stock is owned by institutional investors and hedge funds.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.
Recommended Story: Inverted Yield Curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.